Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chern-En Chiang

Showing results (211-220 of 246) with videos related to

Pageof 25
Sort By:
European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
Cardiovascular Diabetology|August 1, 2021
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataKamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, et al.
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
European Journal of Heart Failure|April 29, 2025
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HFToru Kondo, Pardeep S Jhund, Alasdair D Henderson, et al.
The American Journal of Cardiology|December 11, 2012
Permanent pacemaker implantation for late atrioventricular block in patients receiving catheter ablation for atrioventricular nodal reentrant tachycardiaJo-Nan Liao, Yu-Feng Hu, Tsu-Juey Wu, et al.
JAMA Cardiology|June 18, 2025
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
Nature Medicine|March 18, 2023
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
Journal of the American College of Cardiology|November 9, 2024
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFMingming Yang, Alasdair D Henderson, Atefeh Talebi, et al.
Nature Medicine|December 15, 2022
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
Pageof 25

Showing results (211-220 of 246) with videos related to

Sort By:
Pageof 25
European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
Cardiovascular Diabetology|August 1, 2021
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataKamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, et al.
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
European Journal of Heart Failure|April 29, 2025
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HFToru Kondo, Pardeep S Jhund, Alasdair D Henderson, et al.
The American Journal of Cardiology|December 11, 2012
Permanent pacemaker implantation for late atrioventricular block in patients receiving catheter ablation for atrioventricular nodal reentrant tachycardiaJo-Nan Liao, Yu-Feng Hu, Tsu-Juey Wu, et al.
JAMA Cardiology|June 18, 2025
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
Nature Medicine|March 18, 2023
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
Journal of the American College of Cardiology|November 9, 2024
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFMingming Yang, Alasdair D Henderson, Atefeh Talebi, et al.
Nature Medicine|December 15, 2022
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
Pageof 25